AXLA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AXLA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-04), Axcella Health's share price is $0.4009. Axcella Health's Book Value per Share for the quarter that ended in Jun. 2023 was $-0.77. Hence, Axcella Health's PB Ratio of today is .
The historical rank and industry rank for Axcella Health's PB Ratio or its related term are showing as below:
During the past 6 years, Axcella Health's highest PB Ratio was 45.00. The lowest was 0.00. And the median was 0.00.
During the past 12 months, Axcella Health's average Book Value Per Share Growth Rate was -117.30% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -72.10% per year.
During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Axcella Health was -72.10% per year. The lowest was -72.10% per year. And the median was -72.10% per year.
The historical data trend for Axcella Health's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Axcella Health Annual Data | |||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||
PB Ratio | Get a 7-Day Free Trial | - | 1.54 | 2.59 | 3.72 | 5.79 |
Axcella Health Quarterly Data | ||||||||||||||||||||
Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | |
PB Ratio | Get a 7-Day Free Trial | 11.49 | - | 5.79 | 48.58 | - |
For the Biotechnology subindustry, Axcella Health's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Axcella Health's PB Ratio distribution charts can be found below:
* The bar in red indicates where Axcella Health's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Axcella Health's PB Ratio for today is calculated as follows:
PB Ratio | = | Share Price | / | Book Value per Share (Q: Jun. 2023) |
= | 0.4009 | / | -0.766 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
PB Ratio | = | Market Cap | / | (Total Stockholders Equity | - | Preferred Stock) |
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Axcella Health (OTCPK:AXLA) PB Ratio Explanation
Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Thank you for viewing the detailed overview of Axcella Health's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Paul Fehlner | officer: Senior Vice President, CIPO | C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
William Hinshaw | director, officer: President and CEO | C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
L.p. Fpa, | 10 percent owner | 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142 |
Fpa General Partner Llc | 10 percent owner | 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142 |
Societe Des Produits Nestle S.a. | 10 percent owner | AVENUE NESTLE 55, VEVEY V8 CH-1800 |
Flagship Pioneering Inc. | 10 percent owner | 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142 |
Flagship Ventures Fund Iv, L.p. | 10 percent owner | 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142 |
Torben Straight Nissen | director | C/O RUBIUS THERAPEUTICS, 325 VASSAR ST., STE. 1A, CAMBRIDGE MA 02139 |
Robert L. Rosiello | director | 400 SOMERSET CORPORATE BOULEVARD, BRIDGEWATER NJ 08807 |
Margaret Koziel | officer: Chief Medical Officer | C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Michael Rosenblatt | director | 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033 |
Martin Hendrix | director | C/O PROMETHEUS BIOSCIENCES, INC., 9410 CARROLL PARK DRIVE, SAN DIEGO CA 92121 |
Paul J Sekhri | director | C/O VEEVA SYSTEMS INC., 4637 CHABOT DRIVE, SUITE 210, PLEASANTON CA 94588 |
David R Epstein | director | INTERNATIONAL FLAVORS & FRAGRANCES INC., 521 W. 57TH STREET, NEW YORK NY 10019 |
Robert Crane | officer: Chief Financial Officer | 101 CONVENTION CENTER DRIVE SUITE 310, LAS VEGAS NV 89109 |
From GuruFocus
By Business Wire Business Wire • 12-15-2022
By PRNewswire PRNewswire • 02-15-2022
By PRNewswire PRNewswire • 02-28-2022
By Business Wire Business Wire • 08-02-2022
By Business Wire Business Wire • 03-16-2022
By Business Wire Business Wire • 05-19-2022
By Business Wire Business Wire • 08-12-2022
By GuruFocus Research GuruFocus Editor • 10-20-2022
By Business Wire Business Wire • 02-15-2023
By Business Wire • 08-03-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.